BIOAVAILABILITY AND POLYMORPHIC STABILITY CHALLENGES AFFECTING DRUG PRODUCT’S POTENTIAL: A CRITICAL EVALUATION AND PERTINENT SOLUTION

ramakant panda; SRINIVAS LANKALAPALLI

doi:10.22159/ajpcr.2023.v16i11.48177

Authors

ramakant panda Department of Pharmaceutics, GITAM School of Pharmacy, GITAM Deemed University, Rushikonda, Visakhapatnam, Andhra Pradesh, India. https://orcid.org/0009-0002-3938-3283
SRINIVAS LANKALAPALLI Department of Pharmaceutics, GITAM School of Pharmacy, GITAM Deemed University, Rushikonda, Visakhapatnam, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i11.48177

Keywords:

Polymorphism , metastable polymorph , Polymorphic stability , Solubility , permeability , bio-availability , polymorphic transformation

Abstract

Clinical failure remains an ongoing challenge in pharmaceutical drug product development. Solubility and permeability therefore play a very critical role in achieving desired bioavailability and pharmacological response, which in turns affects clinical safety and efficacy significantly. The situation becomes more critical when the drug candidate exhibits polymorphism and undergoes polymorphic transformation due to its meta-stable nature. This review article outlines the available technologies, pertinent regulations, the concepts involved in the enhancement of bioavailability and polymorphic stability to overcome the clinical failures. Various available technologies for bioavailability enhancement such as salification, micronization, complexation, microemulsification, nano emulsification, cocrystal formation, and amorphous solid dispersion with their advantage and disadvantage in formulating a stable drug product containing a polymorphic and meta-stable drug substance. Thermodynamic and kinetic aspects of polymorphic transformation are discussed to understand different excipient and process-induced transformation during manufacturing and shelf life of the drug product. Selecting the right instrument from the analytical toolbox is equally important to understand the diverse nature of polymorphic transformation. This review provides state-of-the-art information available on advanced analytical tools along with their capabilities, advantages, and disadvantage with respect to physical/structural analysis of polymorphs and polymorphic transformation.

Downloads

Download data is not yet available.

References

Siew A. Solving poor solubility to unlock a drug’s potential. Pharm Technol 2015;39:20-7.

Censi R, Di Martino P. Polymorph impact on the bio-availability and stability of poorly soluble drugs. Molecules 2015;20:18759-76.

U.S. Food and Drug Administration. Guidance for Industry-ANDAs: Pharmaceutical Solid Polymorphism; 2007. Available from: fda.gov/ media/71375/download [Last accessed on 2022 Jul 07].

World Health Organization. Polymorphism Draft Chapter for the International Pharmacopoeia. Geneva: World Health Organization; 2018.

U.S. Food and Drug Administration. Guidance for Industry-Regulatory Classification of Pharmaceutical Co-Crystals; 2018. Available from: fda.www.fda.gov/files/drugs/published/Regulatory-Classification-of- Pharmaceutical-Co-Crystals.pdf [Last accessed on 2022 Jul 07].

U.S. Food and Drug Administration. H.H.S. International Conference on Harmonisation. Guidance on Q6A specififications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances; 2000. Available from: www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products [Last accessed on 2022 Jul 07].

Kwokal A. Preparation, stabilisation and advantages of metastable polymorphs, NATO science for peace and security series A: chemistry and biology. Roberts KJ, Docherty R, Tamura R, editors. Engineering Crystallography: From Molecule to Crystal to Functional Form. Berlin: Springer; 2017. p. 247-59.

Alsirawan M, Paradkar A. Impact of the polymorphic form of drugs/ NCEs on preformulation and formulation development. In: Innovative Dosage Forms: Design and Development at Early Stage. 1st ed. United States: John Wiley and Sons; 2020. p. 1-47.

U.S. Food and Drug Administration. Guidance for Industry- Biopharmaceutics Classification System Based Biowaivers; 2021. Available from: www.fda.gov/media/148472/download [Last accessed on 2022 Jul 07].

European Medicines Agency. Guideline on the Investigation of Bioequivalence; 2010. Available from: www.ema.europa. eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf [Last accessed on 2022 Jul 07].

Nguyen TT, Duong VA, Maeng HJ. Pharmaceutical formulations with P-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bio-availability. Pharmaceutics 2021;13:1103.

Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: In vitro/in vivo case studies. J Pharm Sci 2007;96:235-48.

Kou L, Sun R, Bhutia YD, Yao Q, Chen R. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery. Expert Opin Drug Deliv 2018;15:869-79.

Guan Y, Wang LY, Wang B, Ding MH, Bao YL, Tan SW. Recent advances of D-α-tocopherol polyethylene glycol 1000 succinate based stimuli-responsive nano-medicine for cancer treatment. Curr Med Sci 2020;40:218-31.

Ahmad J, Amin S, Rahman M, Rub RA, Singhal M, Ahmad MZ, et al. Solid matrix based lipidic nanoparticles in oral cancer chemotherapy: Applications and pharmacokinetics. Curr Drug Metab 2015;16:633-44.

Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res 2008;25:500-11.

Airaksinen S, Luukkonen P, Jørgensen A, Karjalainen M, Rantanen J, Yliruusi J. Effects of excipients on hydrate formation in wet masses containing theophylline. J Pharm Sci 2003;92:516-28.

Paisana MC, Wahl MA, Pinto JF. Effect of polymers in moisture sorption and physical stability of polymorphic olanzapine. Eur J Pharm Sci 2017;97:257-68.

Srirambhatla VK, Guo R, Price SL, Florence AJ. Isomorphous template induced crystallisation: A robust method for the targeted crystallisation of computationally predicted metastable polymorphs. Chem Commun (Camb) 2016;52:7384-6.

Telford R, Seaton CC, Clout A, Buanz A, Gaisford S, Williams GR, et al. Stabilisation of metastable polymorphs: the case of paracetamol form III. Chem Commun (Camb) 2016;52:12028-31.

Beckmann W, Nickisch K, Budde U. Development of a seeding technique for the crystallization of the metastable a modifification of abecarnil. Org Process Res Dev 1998;2:298-304.

Van Duong T, Lüdeker D, Van Bockstal PJ, De Beer T, Van Humbeeck J, Van den Mooter G. Polymorphism of indomethacin in semi-crystalline dispersions: Formation, transformation, and segregation. Mol Pharm 2018;15:1037-51.

Chyall LJ, Tower JM, Coates DA, Houston TL, Childs SL. Polymorph generation in capillary spaces: The preparation and structural analysis of a metastable polymorph of nabumetone. Cryst Growth Des 2002;2:505-10.

Al-Ani AJ, Herdes C, Wilson CC, Castro-Dominguez B. Engineering a new access route to metastable polymorphs with electrical confifinement. Cryst Growth Des 2020;20:1451-7.

Joseph S, Rappolt M, Schoenitz M, Huzhalska V, Augustin W, Scholl S, et al. Stability of the metastable α-polymorph in solid triglyceride drug-carrier nanoparticles. Langmuir 2015;31:6663-74.

Nartowski KP, Tedder J, Braun DE, Fábián L, Khimyak YZ. Building solids inside nano-space: From confined amorphous through confined solvate to confined ‘metastable’ polymorph. Phys Chem Chem Phys 2015;17:24761-73.

Gu CH, Chatterjee K, Young V, Grant DJ. Stabilization of a metastable polymorph of sulfamerazine by structurally related additives. J Cryst Growth 2002;235:471-81.

Ehmann HM, Werzer O. Surface mediated structures: Stabilization of metastable polymorphs on the example of paracetamol. Cryst Growth Des 2014;14:3680-4.

Davey RJ, Blagden N, Potts GD, Docherty R. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J Am Chem Soc 1997;119:1767-72.

Banerjee M, Brettmann B. Stabilization of metastable indomethacin α in cellulose nanocrystal aerogel scaffolds. Pharmaceutics 2021;13:441.

Zong Z, Desai SD, Kaushal AM, Barich DH, Huang HS, Munson EJ, et al. The stabilizing effect of moisture on the solid-state degradation of gabapentin. AAPS PharmSciTech 2011;12:924-31.

Krishnan BP, Sureshan KM. A spontaneous single-crystal-to-single-crystal polymorphic transition involving major packing changes. J Am Chem Soc 2015;137:1692-6. doi: 10.1021/ja512697g

Wang JR, Li S, Zhu B, Mei X. Insight into the conformational polymorph transformation of a block-buster multiple sclerosis drug fingolimod hydrochloride (FTY 720). J Pharm Biomed Anal 2015;109:45-51. doi: 10.1016/j.jpba.2015.02.018

Zhang GG, Law D, Schmitt EA, Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 2004;56:371-90. doi: 10.1016/j. addr.2003.10.009, PMID: 14962587

Simões RG, Salzmann I, Resel R, Röthel C, Geerts YH. Stabilization of the metastable Form I of piracetam by crystallization on silicon oxide surfaces. Cryst Growth Des 2018;18:4123-9.

Dharani S, Barakh Ali SF, Afrooz H, Khan MA, Rahman Z. Studying effect of glyceryl palmitostearate amount, manufacturing method and stability on polymorphic transformation and dissolution of rifaximin tablets. Int J Pharm 2020;589:119785.

Sládková V, Dammer O, Kratochvíl B. Solid forms of tenofovir disoproxil fumarate, their mutual conversion, and stabilization of Form I in formulation. J Pharm Sci 2016;105:3136-42.

Tinmanee R, Stamatis SD, Ueyama E, Morris KR, Kirsch LE. Polymorphic and covalent transformations of gabapentin in binary excipient mixtures after milling-induced stress. Pharm Res 2018;35:39.

Shimpi S, Mahadik K, Takada K, Paradkar A. Application of polyglycolized glycerides in protection of amorphous form of etoricoxib during compression. Chem Pharm Bull (Tokyo) 2007;55:1448-51.

Vasa DM, Wildfong PL. Solid-state transformations of ribavirin as a result of high-shear mechanical processing. Int J Pharm 2017;524:339-50. doi: 10.1016/j.ijpharm.2017.04.002

Potter CB, Kollamaram G, Zeglinski J, Whitaker DA, Croker DM, Walker GM. Investigation of polymorphic transitions of piracetam induced during wet granulation. Eur J Pharm Biopharm 2017;119:36-46. doi: 10.1016/j.ejpb.2017.05.012

Otsuka M, Matsumoto T, Kaneniwa N. Effects of the mechanical energy of multi-tableting compression on the polymorphic transformations of chlorpropamide. J Pharm Pharmacol 1989;41:665-9. doi: 10.1111/ j.2042-7158.1989.tb06337.x

Gorkovenko EA, Kichanov SE, Kozlenko DP, Belushkin AV, Wąsicki J, Nawrocik W, et al. The pressure-induced polymorphic transformations in fluconazole. J Pharm Sci 2015;104:4164-9. doi: 10.1002/jps.24644

Neuschitzer M, Moser A, Neuhold A, Kraxner J, Stadlober B, OehzeltM, et al. Grazing incidence in-plane X-ray diffraction on ultra-thin organic films using standard laboratory equipment. J Appl Crystallogr 2012;45:367-70.

Zhang GG, Law D, Schmitt EA, Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 2004;56:371-90.

Li Y, Chow PS, Tan RB. Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy. Int J Pharm 2011;415:110-8. doi: 10.1016/j.ijpharm.2011.05.058, PMID: 21645601

S’ari M, Blade H, Cosgrove S, Drummond-Brydson R, Hondow N, Hughes LP, et al. Characterization of amorphous solid dispersions and identification of low levels of crystallinity by transmission electron microscopy. Mol Pharm 2021;18:1905-19. doi: 10.1021/acs. molpharmaceut.0c00918, PMID: 33797925

Bugay DE. Characterization of the solid-state: Spectroscopic techniques. Adv Drug Deliv Rev 2001;48:43-65. doi: 10.1016/s0169- 409x(01)00101-6, PMID: 11325476

Urakami K. Characterization of pharmaceutical polymorphs by isothermal calorimetry. Curr Pharm Biotechnol 2005;6:193-203. doi: 10.2174/1389201054022904, PMID: 15974974

Offerdahl TJ, Munson EJ. Solid-State NMR Spectroscopy. United States: McGraw-Hill Education; 2004.

Yuan X, Sperger D, Munson EJ. Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy. Mol Pharm 2014;11:329-37. doi: 10.1021/ mp400498n

Yi Li, Chow PS, Tan RB. Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy. Int J Pharm 2011;415:110-8. doi: 10.1016/j.ijpharm.2011.05.058

Neuschitzer M, Moser A, Neuhold A, Kraxner J, Stadlober B, OehzeltM, et al. Grazing incidence in-plane X-ray diffraction on ultra-thin organic films using standard laboratory equipment. J Appl Crystallogr 2012;45:367-70.

Louer D, Louer M, Dzyabchenko V, Agafonov V, Ceolin R. Structure of a metastable phase of piracetami from X-ray powder diffraction using the atom-atompotential method. Acta Crystallogr Sect B Struct Sci 1995;51:182-7.

Kuhnert-Brandstatter M, Burger A, Vollenkee R. Stability behaviour of piracetam polymorphs. Sci Pharm 1994;62:307-16.

Van Arnum P. Advancing approaches in detecting polymorphism. Pharm Technol 2007;2007: 4.

Urakami K. Characterization of pharmaceutical polymorphs by isothermal calorimetry. Curr Pharm Biotechnol 2005;6:193-203. doi: 10.2174/1389201054022904, PMID: 15974974

Offerdahl TJ, Munson EJ. Solid-State NMR Spectroscopy. United States: McGraw-Hill Education; 2004.

Yuan X, Sperger D, Munson EJ. Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy. Mol Pharm 2014;11:329-37. doi: 10.1021/ mp400498n

Okada K, Hirai D, Kumada S, Kosugi A, Hayashi Y, Onuki Y. 1H NMR relaxation study to evaluate the crystalline state of active pharmaceutical ingredients containing solid dosage forms using time domain NMR. J Pharm Sci 2019;108:451-6.

Bugay DE. Characterization of the solid-state: Spectroscopic techniques. Adv Drug Deliv Rev 2001;48:43-65. doi: 10.1016/s0169- 409x(01)00101-6, PMID: 11325476

Strachan CJ, Taday PF, Newnham DA, Gordon KC, Zeitler JA, Pepper M, et al. Using terahertz pulsed spectroscopy to quantify pharmaceutical polymorphism and crystallinity. J Pharm Sci 2005;94:837-46. doi: 10.1002/jps.20281. PMID: 15736195

Donahue MM, Botonjic-Sehic E, Wells D, Brown CW. Understanding infrared and Raman spectra of pharmaceutical polymorphs. Am Pharm Rev 2011;14: 1-12.

McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, et al. Use of a glutaric acid cocrystal to improve oral bio-availability of a low solubility API. Pharm Res 2006;23:1888-97. doi: 10.1007/ s11095-006-9032-3